Compare SKYE & TOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SKYE | TOP |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 43.0M |
| IPO Year | N/A | 2022 |
| Metric | SKYE | TOP |
|---|---|---|
| Price | $0.93 | $1.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $14.75 | N/A |
| AVG Volume (30 Days) | ★ 263.7K | 43.2K |
| Earning Date | 11-10-2025 | 01-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,329,256.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.99 | $1.00 |
| 52 Week High | $5.75 | $3.33 |
| Indicator | SKYE | TOP |
|---|---|---|
| Relative Strength Index (RSI) | 31.94 | 41.34 |
| Support Level | $1.04 | $1.07 |
| Resistance Level | $1.27 | $1.17 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 4.55 | 38.13 |
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.